Prelude Therapeutics (PRLD) Income from Continuing Operations (2019 - 2026)
Prelude Therapeutics (PRLD) posted Income from Continuing Operations of 34444000.0 for Q1 2026, down 90.49% sequentially from 18082000.0 in Q4 2025, and up 40.15% YoY from 24576806.56 in Q1 2025.
Prelude Therapeutics (PRLD) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Prelude Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 34444000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 40.15% year-over-year to 34444000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 149013000.0 (up 39.97% YoY) and the FY2025 annual result came in at 316470000.0, up 1.83% from the prior year.
- Income from Continuing Operations retreated to 34444000.0 in Q1 2026 per PRLD's latest filing, from 18082000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 18082000.0 in Q4 2025 and troughed at 144438000.0 in Q4 2022.
- A 5-year average of 52379294.12 and a median of 41588000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations jumped 83.64% in 2022, then plunged 112.54% in 2024.
- Over 5 years, Income from Continuing Operations stood at 144438000.0 in 2022, then jumped by 73.79% to 37861000.0 in 2023, then gained by 9.24% to 34363000.0 in 2024, then surged by 47.38% to 18082000.0 in 2025, then tumbled by 90.49% to 34444000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 34444000.0, 18082000.0, and 42020000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Prelude Therapeutics | 442.91 Mn | 162.28 Mn | - | -52.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.71 Mn |
| Mar 31, 2026 | -34.44 Mn |
| Dec 31, 2025 | -18.08 Mn |
| Sep 30, 2025 | -42.02 Mn |
| Jun 30, 2025 | -54.47 Mn |
| Mar 31, 2025 | -57.55 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | -76.48 Mn |
| Jun 30, 2024 | -79.85 Mn |
| Mar 31, 2024 | -77.64 Mn |
| Dec 31, 2023 | -37.86 Mn |
| Sep 30, 2023 | -35.99 Mn |
| Jun 30, 2023 | -37.80 Mn |
| Mar 31, 2023 | -38.22 Mn |
| Dec 31, 2022 | -144.44 Mn |
| Sep 30, 2022 | -42.51 Mn |
| Jun 30, 2022 | -37.16 Mn |
| Mar 31, 2022 | -41.59 Mn |
| Dec 31, 2021 | -108.38 Mn |
| Sep 30, 2021 | -170.14 Mn |